Teva Pharmaceutical Industries (NYSE:TEVA) Insider Eric Hughes Sells 9,533 Shares

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) insider Eric Hughes sold 9,533 shares of the stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $31.67, for a total transaction of $301,910.11. Following the sale, the insider owned 107,711 shares in the company, valued at $3,411,207.37. The trade was a 8.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Teva Pharmaceutical Industries Price Performance

TEVA stock opened at $31.44 on Tuesday. The company’s 50-day moving average price is $33.01 and its two-hundred day moving average price is $26.41. The firm has a market cap of $36.15 billion, a P/E ratio of 26.20, a P/E/G ratio of 10.39 and a beta of 0.72. The company has a quick ratio of 0.80, a current ratio of 1.04 and a debt-to-equity ratio of 1.89. Teva Pharmaceutical Industries Ltd. has a 12 month low of $12.47 and a 12 month high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share for the quarter, topping analysts’ consensus estimates of $0.65 by $0.31. The company had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.36 billion. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The firm’s quarterly revenue was up 11.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.71 EPS. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. On average, analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Institutional Trading of Teva Pharmaceutical Industries

A number of hedge funds and other institutional investors have recently modified their holdings of TEVA. Aster Capital Management DIFC Ltd acquired a new position in shares of Teva Pharmaceutical Industries during the fourth quarter worth $25,000. Allworth Financial LP boosted its holdings in shares of Teva Pharmaceutical Industries by 53.8% during the 4th quarter. Allworth Financial LP now owns 941 shares of the company’s stock valued at $29,000 after acquiring an additional 329 shares in the last quarter. Grove Bank & Trust boosted its holdings in shares of Teva Pharmaceutical Industries by 300.0% during the 4th quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock valued at $31,000 after acquiring an additional 750 shares in the last quarter. EverSource Wealth Advisors LLC grew its position in Teva Pharmaceutical Industries by 51.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock worth $32,000 after acquiring an additional 345 shares during the last quarter. Finally, Advisors Asset Management Inc. bought a new stake in Teva Pharmaceutical Industries during the 2nd quarter worth $41,000. Institutional investors own 54.05% of the company’s stock.

Key Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Q4 results and FY‑2026 guidance remain a tailwind — Teva posted an EPS and revenue beat for the most recent quarter and set FY‑2026 EPS guidance of 2.570–2.770, with year‑over‑year revenue growth of ~11.4%. Those fundamentals help explain the stock’s strength today. MarketBeat TEVA coverage
• Neutral Sentiment: Management presented at the Leerink Global Healthcare Conference — a verbatim transcript of the presentation is available; investor focus will be on any pipeline updates, margin commentary or capital allocation remarks that could support the company’s outlook. Leerink presentation transcript
• Negative Sentiment: Significant insider selling disclosed (March 5 filings) — multiple executives sold shares at an average price of $31.67, including CEO Richard D. Francis (20,025 shares), EVP Richard Daniell (17,295), Placid Jover (14,150), Eric A. Hughes (9,533), Christine Fox (7,924) and Brian Savage (1,127). These disclosed sales reduce insider positions and may be read negatively by some investors; supporting SEC filings are available. Example SEC filing (CEO sale)
• Negative Sentiment: Media coverage highlights large CEO share sales — an American Banking News story flagged substantial CEO selling, which can amplify investor caution even when sales are routine or pre‑planned. Insider selling article

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on TEVA shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, January 21st. Piper Sandler reissued an “overweight” rating and set a $41.00 price target (up from $40.00) on shares of Teva Pharmaceutical Industries in a report on Wednesday, March 4th. Scotiabank upped their price objective on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a “sector outperform” rating in a research report on Thursday, January 29th. Wall Street Zen raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 31st. Finally, Jefferies Financial Group lifted their target price on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $37.67.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.